Magnesium in CKD: more than a calcification inhibitor?

Journal of Nephrology

Volumn 28, Issue 3, 2015, Pages 269-277

  Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Cardiovascular disease; Chronic kidney disease; Depression; Diabetes; Magnesium

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; GLYCOGEN SYNTHASE KINASE 3; MAGNESIUM; MAGNESIUM CARBONATE; N METHYL DEXTRO ASPARTIC ACID;

BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DEPRESSION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FATIGUE; HEALTH STATUS; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOMAGNESEMIA; LIFESTYLE MODIFICATION; MAGNESIUM BLOOD LEVEL; MAGNESIUM INTAKE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BONE; COMORBIDITY; DIETARY SUPPLEMENT; KIDNEY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; VASCULAR CALCIFICATION;

ANIMALS; BONE AND BONES; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIETARY SUPPLEMENTS; FATIGUE; HEALTH STATUS; HUMANS; HYPERTENSION; KIDNEY; MAGNESIUM; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84930194876     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0140-6     Document Type: Review

References (86)

1. Luft C (2012) Magnesium—a versatile and often overlooked element: new perspectives with a focus on chronic kidney disease. Clin Kidney J 5(Suppl 1). doi:10.1093/ndtplus/sfs035
2. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R (2013) Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 126(9):825–831. doi:10.1016/j.amjmed.2013.02.036
3. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y (2014) Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85(1):174–181. doi:10.1038/ki.2013.327
4. Alves SC, Tomasi CD, Constantino L et al (2013) Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28(4):910–916. doi:10.1093/ndt/gfs268
5. Foley RN, Parfrey PS (1998) Cardiovascular disease and mortality in ESRD. J Nephrol 11(5):239–245
6. Shanahan CM (2006) Vascular calcification—a matter of damage limitation? Nephrol Dial Transplant 21(5):1166–1169. doi:10.1093/ndt/gfl089
7. London GM (2013) Mechanisms of arterial calcifications and consequences for cardiovascular function. Kidney Int Suppl 3:442–445. doi:10.1038/kisup.2013.92
8. Massy ZA, Drüeke TB (2012) Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 5(Suppl 1):i52–i61. doi:10.1093/ndtplus/sfr167
9. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM (2003) Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23(3):489–494. doi:10.1161/01.ATV.0000059406.92165.31
10. Peters F, Epple M (2001) Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under controlled conditions. Z Kardiol 90(Suppl3):81–85. doi:10.1007/s003920170047
11. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A (1987) Mg2+–Ca2+ interaction in contractility of vascular smooth muscle: Mg2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 65(4):729–745. doi:10.1139/y87-120
12. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drüeke TB, Massy ZA (2005) The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 67(6):2288–2294. doi:10.1111/j.1523-1755.2005.00332.x
13. Salem S, Bruck H, Bahlmann FH et al (2012) Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 35(1):31–39. doi:10.1159/000334742
14. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, Steppan S, Asci G, Ok E, Passlick-Deetjen J (2012) Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 27(2):514–521. doi:10.1093/ndt/gfr321
15. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA (2013) Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 28(4):869–878. doi:10.1093/ndt/gfs520
16. Montes de Oca A, Guerrero F, Martinez-Moreno JM et al (2014) Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS ONE 9(2):e89525. doi:10.1371/journal.pone.0089525
17. Fischer DC, Behetes GJ, Hakenberg OW, Voigt M, Vervaet BA, Robijn S, Kundt G, Schareck W, D’Haese PC, Haffner D (2012) Arterial microcalcification in atherosclerotic patients with and without chronic kidney disease: a comparative high-resolution scanning X-ray diffraction analysis. Calcif Tissue Int 90(6):465–472. doi:10.1007/s00223-012-9594-5
18. Van Laecke S, Maréchal C, Verbeke F, Peeters P, Van Biesen W, Devuyst O, Jadoul M, Vanholder R (2011) The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant 26(7):2362–2369. doi:10.1093/ndt/gfq728
19. Kanbay M, Yilmaz MI, Apetrii M et al (2012) Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36(3):228–237. doi:10.1159/000341868
20. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, Minagar A (2013) Effect of magnesium supplementation on carotid intima–media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 69(5):309–316. doi:10.1159/000346427
21. Turgut F, Kanbay M, Metin M, Uz E, Akcay A, Covic A (2008) Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40(4):1075–1082. doi:10.1007/s11255-008-9410-3
22. Qu X, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K (2013) Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE 8(3):e57720. doi:10.1371/journal.pone.0057720
23. Guasch-Ferré M, Bulló M, Estruch R et al (2014) Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr 144(1):55–60. doi:10.3945/jn.113.183012
24. Fragoso A, Silva AP, Gundlach K, Janine Büchel J, Leão Neves P (2014) Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients. Clin Kidney J 7(2):161–166. doi:10.1093/ckj/sfu003
25. Silva AP, Fragoso A, Silva C, Tavares N, Santos N, Martins H, Gundlach K, Büchel J, Camacho A, Faísca M, Jesus Varela I, Neves P (2014) Magnesium and mortality in patients with diabetes and early chronic kidney disease. J Diabetes Metab 5:347. doi:10.4172/2155-6156.1000347
26. Shechter M (2003) Does magnesium have a role in the treatment of patients with coronary artery disease? Am J Cardiovasc Drugs 3(4):231–239. doi:10.2165/00129784-200303040-00001
27. Matsuzaki H, Kajita Y, Miwa M (2013) Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats. Magnes Res 26(1):18–23. doi:10.1684/mrh.2013.0331
28. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL (2013) A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 28(9):2383–2392. doi:10.1093/ndt/gft203
29. Iguchi A, Watanabe Y, Iino N, Kazama JJ, Iesato H, Narita I (2014) Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients. Nephrology. 10.1111/nep.12287
30. Brown EM (1991) Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 71:371–411
31. Kumar R, Thompson JR (2011) The regulation of parathyroid hormone secretion and synthesis. J Am Soc Nephrol 22(2):216–224. doi:10.1681/ASN.2010020186
32. Quinn SJ, Thomsen AR, Egbuna O, Pang J, Baxi K, Goltzman D, Pollak M, Brown EM (2013) CaSR-mediated interactions between calcium and magnesium homeostasis in mice. Am J Physiol Endocrinol Metab 304(7):E724–E733. doi:10.1152/ajpendo.00557.2012
33. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25(11):3707–3717. doi:10.1093/ndt/gfq292
34. Rodríguez-Ortiz ME, Canalejo A, Herencia C et al (2014) Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expressions at moderately low calcium concentration. Nephrol Dial Transplant 29(2):282–289. doi:10.1093/ndt/gft400
35. Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116(8):2062–2072. doi:10.1172/JCI29449
36. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S (2012) Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 95(1):91–100. doi:10.3945/ajcn.111.014779
37. Schöttker B, Ball D, Gellert C, Brenner H (2013) Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 12(2):708–718. doi:10.1016/j.arr.2012.02.004
38. Risco F, Traba ML (1992) Influence of magnesium on the in vitro synthesis of 24,25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3. Magnes Res 5(1):5–14
39. Rude RK, Adams JS, Ryzen E, Endres DB, Niimi H, Horst RL, Haddad JG Jr, Singer FR (1985) Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency. J Clin Endocrinol Metab 61(5):933–940. doi:10.1210/jcem-61-5-933
40. Risco F, Traba ML (1994) Possible involvement of a magnesium dependent mitochondrial alkaline phosphatase in the regulation of the 25-hydroxyvitamin D3-1 alpha-and 25-hydroxyvitamin D3-24R-hydroxylases in LLC-PK1 cells. Magnes Res 7(3–4):169–178
41. Rösler A, Rabinowitz D (1973) Magnesium-induced reversal of vitamin-D resistance in hypoparathyroidism. Lancet 1(7807):803–804. doi:10.1016/S0140-6736(73)90602-8
42. Deng X, Song Y, Manson JE, Signorello LB, Zhang SM, Shrubsole MJ, Ness RM, Seidner DL, Dai Q (2013) Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Med 11:187. doi:10.1186/1741-7015-11-187
43. Cunningham J, Rodríguez M, Messa P (2012) Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J 5(Suppl 1):i39–i51. doi:10.1093/ndtplus/sfr166
44. Rude RK, Singer FR, Gruber HE (2009) Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr 28(2):131–141
45. Witteman JC, Willett WC, Stampfer MJ, Colditz GA, Sacks FM, Speizer FE, Rosner B, Hennekens CH (1989) A prospective study of nutritional factors and hypertension among US women. Circulation 80(5):1320–1327. doi:10.1161/01.CIR.80.5.1320
46. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ (1992) A prospective study of nutritional factors and hypertension among US men. Circulation 86(5):1475–1484. doi:10.1161/01.CIR.86.5.1475
47. Ascherio A, Hennekens C, Willett WC, Sacks F, Rosner B, Manson J, Witteman J, Stampfer MJ (1996) Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27(5):1065–1072. doi:10.1161/01.HYP.27.5.1065
48. Song Y, Sesso HD, Manson JE, Cook NR, Buring JE, Liu S (2006) Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol 98(12):1616–1621. doi:10.1016/j.amjcard.2006.07.040
49. Elwood PC, Fehily AM, Ising H, Poor DJ, Pickering J, Kamel F (1996) Dietary magnesium does not predict ischaemic heart disease in the Caerphilly cohort. Eur J Clin Nutr 50(10):694–697
50. Song Y, Manson JE, Cook NR, Albert CM, Buring JE, Liu S (2005) Dietary magnesium intake and risk of cardiovascular disease among women. Am J Cardiol 96(8):1135–1141. doi:10.1016/j.amjcard.2005.06.045
51. Al-Delaimy WK, Rimm EB, Willett WC, Stampfer MJ, Hu FB (2004) Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr 23(1):63–70
52. Liao F, Folsom AR, Brancati FL (1998) Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 136(3):480–490. doi:10.1016/S0002-8703(98)70224-8
53. Ford ES (1999) Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 28(4):645–651. doi:10.1093/ije/28.4.645
54. Abbott RD, Ando F, Masaki KH, Tung KH, Rodriguez BL, Petrovitch H, Yano K, Curb JD (2003) Dietary magnesium intake and the future risk of coronary heart disease (the Honolulu Heart Program). Am J Cardiol 92(6):665–669. doi:10.1016/S0002-9149(03)00819-1
55. Xing JH, Soffer EE (2001) Adverse effects of laxatives. Dis Colon Rectum 44(8):1201–1209
56. Joosten MM, Gansevoort RT, Mukamal KJ, Kootstra-Ros JE, Feskens EJ, Geleijnse JM, Navis G, Bakker SJ, PREVEND Study Group (2013) Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension 61(6):1161–1167. doi:10.1161/HYPERTENSIONAHA.113.01333
57. Joosten MM, Gansevoort RT, Mukamal KJ, van der Harst P, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ, PREVEND Study Group (2013) Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 97(6):1299–1306. doi:10.3945/ajcn.112.054114
58. Rodríguez-Moran M, Guerrero-Romero F (2014) Hypomagnesemia and prehypertension in otherwise healthy individuals. Eur J Intern Med 25(2):128–131. doi:10.1016/j.ejim.2013.08.706
59. Dickinson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR, Ford GA, Mason J (2006) Magnesium supplementation for the management of primary hypertension in adults (Review). Cochrane Database Syst Rev 3:1–55. doi:10.1002/14651858.CD004639.pub2
60. Rosanoff A (2010) Significant first presence of Mg symposium at experimental biology, a large USA conference. Magnes Res 23(4):S180. doi:10.1684/mrh.2010.0223
61. ERA-EDTA Registry (2012) ERA-EDTA Registry Annual Report 2010. Academic Medical Center, Department of Medical Informatics, Amsterdam
62. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT (2007) Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2(2):366–373. doi:10.2215/CJN.02960906
63. Dong JY, Xun P, He K, Qin LQ (2011) Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 34(9):2116–2122. doi:10.2337/dc11-0518
64. Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, Yanagawa N, Pham PT (2005) Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 63(6):429–436
65. Paolisso G, Sgambato S, Pizza G, Passariello N, Varricchio M, D’Onofrio F (1989) Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 12(4):265–269. doi:10.2337/diacare.12.4.265
66. Rodríguez-Morán M, Guerrero-Romero F (2003) Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26(4):1147–1152. doi:10.2337/diacare.26.4.1147
67. Huang JH, Lu YF, Cheng FC, Lee JN, Tsai LC (2012) Correlation of magnesium intake with metabolic parameters, depression and physical activity in elderly type 2 diabetes patients: a cross-sectional study. Nutr J 11:41. doi:10.1186/1475-2891-11-41
68. Sales CH, Pedrosa LF, Lima JG, Lemos TM, Colli C (2011) Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. Clin Nutr 30(3):359–364. doi:10.1016/j.clnu.2010.12.011
69. Escobedo LG, Caspersen CJ (1997) Risk factors for sudden coronary death in the United States. Epidemiology 8(2):175–180
70. Del Gobbo LC, Song Y, Poirier P, Dewailly E, Elin RJ, Egeland GM (2012) Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol 11:23. doi:10.1186/1475-2840-11-23
71. Song Y, Hsu YH, Niu T, Manson JE, Buring JE, Liu S (2009) Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 10:4. doi:10.1186/1471-2350-10-4
72. Nair AV, Hocher B, Verkaart S et al (2012) Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci USA 109(28):11324–11329. doi:10.1073/pnas.1113811109
73. Prabodh S, Prakash DS, Sudhakar G, Chowdary NV, Desai V, Shekhar R (2011) Status of copper and magnesium levels in diabetic nephropathy cases: a case–control study from South India. Biol Trace Elem Res 142(1):29–35. doi:10.1007/s12011-010-8750-x
74. Sakaguchi Y, Shoji T, Hayashi T et al (2012) Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 35(7):1591–1597. doi:10.2337/dc12-0226
75. Bonner A, Wellard S, Caltabiano M (2008) Levels of fatigue in people with ESRD living in far North Queensland. Clin Nurs 17(1):90–98. doi:10.1111/j.1365-2702.2007.02042.x
76. Horigan A, Rocchiccioli J, Trimm D (2012) Dialysis and fatigue: implications for nurses—a case study analysis. Medsurg Nurs 21(3):158–163
77. Hedayati SS, Yalamanchili V, Finkelstein FO (2012) A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int 81(3):247–255. doi:10.1038/ki.2011.358
78. Li X, Frye MA, Shelton RC (2012) Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 37(1):77–101. doi:10.1038/npp.2011.198
79. Murck H (2013) Ketamine, magnesium and major depression—from pharmacology to pathophysiology and back. J Psychiatr Res 47(7):955–965. doi:10.1016/j.jpsychires.2013.02.015
80. Szewczyk B, Poleszak E, Sowa-Kućma M et al (2008) Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 60(5):588–589
81. Socała K, Nieoczym D, Poleszak E, Wlaź P (2012) Influence of the phosphodiesterase type 5 inhibitor, sildenafil, on antidepressant-like activity of magnesium in the forced swim test in mice. Pharmacol Rep 64(1):205–211
82. Poleszak E, Szewczyk B, Kedzierska E, Wlaź P, Pilc A, Nowak G (2004) Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 78(1):7–12. doi:10.1016/j.pbb.2004.01.006
83. Cox IM, Campbell MJ, Dowson D (1991) Red blood cell magnesium and chronic fatigue syndrome. Lancet 337(8744):757–760. doi:10.1016/0140-6736(91)91371-Z
84. Barragán-Rodríguez L, Rodríguez-Morán M, Guerrero-Romero F (2008) Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res 21(4):218–223. doi:10.1684/mrh.2008.0149
85. Maduell F, Pérez N, Arias M et al (2012) Calcium acetate and magnesium carbonate association: a good alternative of calcium-based phosphate binders. Nephrol Dial Transplant 27(2):506. doi:10.1093/ndt/gfs245
86. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D’Haese PC, Neven E (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83(6):1109–1117. doi:10.1038/ki.2013.34